BOTULINUM TOXIN TYPE A
Manufacturer: Galderma Laboratories, L.P.
Score: 148.0
Dysport (abobotulinumtoxinA) is a neurotoxin indicated for the treatment of cervical dystonia in adults, temporary improvement in the appearance of moderate to severe glabellar lines in adults under 65, and spasticity in patients 2 years of age and older. The primary mechanism of action is the inhibition of acetylcholine release from peripheral cholinergic nerve endings, resulting in a decrease in muscle activity. Key clinical findings include efficacy in reducing symptoms of cervical dystonia, glabellar lines, and spasticity. Important safety information includes warnings about distant spread of toxin effect, lack of interchangeability with other botulinum toxin products, and potential for hypersensitivity reactions. Main dosing recommendations vary by indication and include initial doses and titration schedules. Special population considerations include use during pregnancy, nursing, pediatric, and geriatric populations, with specific guidance for each group.
Distant spread of toxin effect can occur, causing symptoms such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties
Dose adjustment may be necessary based on individual patient response and adverse reaction history
500 Units given intramuscularly as a divided dose among affected muscles
Not established
50 Units divided in five equal aliquots of 10 Units each
Not recommended
500-1000 Units for upper limb spasticity, 1000-1500 Units for lower limb spasticity
8-16 Units/kg for upper limb spasticity, 10-15 Units/kg for lower limb spasticity